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The terrestrial nematode, Caenorhabditis elegans, is an invaluable model organism for the study 
of molecular and cellular processes due to their small size, rapid generation time, easy 
cultivation, and invariant cell number. Additionally, 40% of genes known to be associated with 
human disease have clear orthologs in the C. elegans genome. In C. elegans genetics research, 
microinjection of genetic material into the worms is critical. Although an established technique, 
manual microinjection is tedious, low-throughput, and requires an expert researcher. This thesis 
details a novel microfluidic device designed to perform high-throughput microinjection. This 
two-layer, PDMS-based chip integrates microfluidic elements to control worm sorting, reduction 
of immobilization time and stress, and novel on-chip microinjection using only a positive 
pressure source. Our project aim is to increase microinjection efficiency, consistency, and 
accessibility to researchers of all experience levels in order to advance genetics research and 
genetic engineering technology in C. elegans. Preliminary results are promising, as our on-chip 
microinjection device has been able to successfully inject dye into C. elegans animals.  
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1. Chapter 1: Introduction 
1.1. Motivation 
The terrestrial nematode, Caenorhabditis elegans, is an invaluable model 
organism for the study of molecular and cellular processes due to its small size, 
rapid generation time, easy cultivation, sequenced genome, and invariant cell 
number. Additionally, 40% of genes known to be associated with human disease 
have clear orthologs in the C. elegans genome. In C. elegans genetics research, 
microinjection of genetic material into the worms is critical to the creation of 
transgenic animals. Although an established technique, manual microinjection is 
tedious, low-throughput and requires an expert, making it a major rate limiting 
step in C. elegans genetic research. Our project goal was to utilize microfluidic 
technology to increase microinjection efficiency, consistency, and accessibility to 
researchers of all experience levels in order to advance genetics research and 
genetic engineering technology in C. elegans.  
1.2. C. elegans background and basics 
C. elegans is a type of terrestrial, transparent nematode that grows to be about 1 
mm in length and 30-45µm in width. While generally found in temperate soil 
environments, these worms can be easily cultivated and studied in the lab. 
 C. elegans has served as an invaluable genetics model organism since the 1970’s 
due to the high degree of similarity found between its cellular and molecular 
processes (i.e. morphogenesis, biochemical signaling pathways, protein coding 
genes) and those found in humans. The C. elegans genome contains orthologs for 
60-80% of human genes, 40% of which are related to human disease states such 
as cancer1. C. elegans has also served as an excellent medium for optimizing 
                                                          





genetic engineering technologies (i.e. CRISPR/Cas 9) as genetics research has 
been conducted on them for decades and knowledge of their genome is well 
established. 
In addition to its value as a genetics model organism, C. elegans possess a number 
of favorable properties making it an excellent research subject. Some of these 
characteristics include: 
● Optical transparency 
● Small size 
● Simple anatomy with fully mapped cell lineages 
● Easy cultivation (grown in petri dishes) 
● Quick generation time (3 days at 23℃) 
● Hermaphroditic (self-fertilization useful in genetics research) 
● Completely sequenced genome 
1.3. Creation of transgenic C. elegans animals using microinjection 
In many C. elegans genetics labs, researchers attempt to alter, disrupt, or replace 
genes in order to study their function. One way to alter the C. elegans genome for 
research purposes is to manually microinject genetic material into a worm’s 
newly forming oocytes. The genetic material can range from simple plasmids to 
genetic engineering constructs and proteins such as CRISPR/Cas 9. For example, 
in Dr. Leilani Miller’s lab at Santa Clara University (SCU), certain sequences of 
the C. elegans genome are edited by injecting plasmids coding for a guided 
CRISPR/Cas 9 construct. This CRISPR/Cas 9 complex cuts and edits certain 
sequences in the worm genome to disrupt the phosphorylation sites of a particular 
transcription factor. This allows her to study the role that phosphorylation of that 
particular protein plays in a biochemical signaling pathway.  
1.4. Limitations of manual microinjection 
To emphasize the tedious nature of manual microinjection, we have outlined the 
key steps of this process below: 
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● Pull a very small glass capillary (external diameter = 1 mm, 
internal diameter = 0.58 mm) into an even smaller glass 
microinjection needle (tip diameter ~ 1µm) 
● Load the needle with injection mix 
● Transfer worm to drop of injection oil on a desiccated agarose pad 
● Manually rotate wriggling 1mm x 40µm worm into the correct 
orientation for injection 
● Manually press the worm against the agarose injection pad so that 
it will adhere and hold still (without popping the worm) 
● Manually puncture the worm’s gonad and flood its distal tip with 
injection mix 
● Remove the worm before it desiccates on the injection pad and 
proceed with recovery process 
Although this is an abbreviated list of the microinjection procedure, we hope that 
it is now apparent how delicate and labor intensive this process can be and why 
many researchers spend years mastering this technique. To see a visual depiction 
of the manual microinjection process, see Appendix A.  
1.5. Critical elements for a successful microinjection 
To properly inject genetic material into a worm, a researcher must insert the 
needle into the worm at the correct angle, on the correct side of their body, and 
apply the perfect amount of force to barely puncture the cuticle of the worm and 
flood its gonad with injection mixture. With this delicate procedure, it is easy for 
a researcher to accidentally kill the animal by pushing too hard, inserting the 
needle at the wrong angle, or by using a blunt needle 
To successfully create transformants, the injected worms must be healthy young 
adult hermaphrodites with plenty of developing oocytes in their gonad2. An 
                                                          
2 Evans et al. “Transformation and microinjection.” WormBook, (2006). 
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optimal injection will puncture and flood the distal tip of one or both of the 
worm’s gonads with the desired genetic construct (Figure 1) 3.  
Successful transformation of germ-line cells is dependent on injection of genetic 
material into the cytoplasmic core of the syncytium located at the distal tip of the 
hermaphrodite’s gonad4 (Figure 1B). This allows the injected genetic material to 
become incorporated into the new eggs as their newly forming plasma membranes 
encapsulate both the oocyte nuclei and the cytoplasm containing the injected 
genetic material. Incorporation of genetic material into the newly formed oocytes 
produces successful genetic transformants. 
                                                          
3 Rieckher et al. “Generation of C. elegans Transgenic Animals by DNA Microinjection.” Bio-protocol (2017). 
4 Evans et al. “Transformation and microinjection.” WormBook, (2006). 
Figure 1. Injection of genetic material into distal tip of C. elegans gonad. 
(A) Schematic showing proper microneedle angle and insertion point into 
worm gonad for a successful microinjection of genetic material. (B) Close-
up of worm gonad showing insertion of microneedle tip into the syncytium 




Given the detailed nature of the microinjection procedure coupled with the 
microscopic size of the target injection site, microinjection is a major rate limiting 
step in C. elegans genetics labs around the world. 
1.6. A primer on microfluidic technology 
Microfluidic technology allows the user to interact with various systems at a 
micron scale. Microfluidic chips have four main advantages: miniaturization, 
increased throughput, low-cost, and potential for automation. Channel dimensions 
are typically <100 μm, providing working volumes within the nanoliter range—
well within the dimensions of C. elegans. 
1.6.1. Fluid properties 
Using an array of channels and valves, users can direct the way that fluid 
flows through microfluidic chips. The primary advantage of working with 
fluids on the micron scale is that the fluids experience laminar flow, this 
means that its fluid dynamics are more easily controlled and understood. 
Additionally, at this scale, researchers are able to use reduced reagent 
volumes which yields a lower overall cost.  
1.6.2. Material properties 
Microfluidic chips are primarily made of polydimethylsiloxane (PDMS), 
an optically clear rubber. Some of the advantages of utilizing PDMS are 
its flexibility (Young’s modulus can be modified by altering the mixture 
of crosslinker to prepolymer), optical transparency, gas permeability, 
biocompatibility, and relatively low cost.   
1.6.3. Application of microfluidics to C. elegans research 
Made from PDMS, microfluidic devices are transparent, permeable to gas, 
non-toxic, and inert; therefore, they are appropriate for biological research. 
Microfluidic devices maintain controlled flows and allow for easy 
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handling and manipulation of C. elegans animals5, making some 
techniques more accessible and previously impossible ones possible. 
1.7. Existing microfluidic microinjection technology 
Before embarking on our design project, we isolated three critical components for 
successful C. elegans microinjection: alignment, immobilization, and lastly, 
microinjection. We conducted a literature review of current microfluidic 
technologies that address these steps and their application in C. elegans research.  
1.7.1. Microfluidic alignment of C. elegans  
In 2016, researchers from York University and Mount Sinai Hospital in 
Canada created a device for orientation and multidirectional imaging of C. 
elegans. Ultimately, they sought to provide lateral and longitudinal 
control. In order to achieve this, they incorporated electrotaxis technology 
into their chip with a rotatable glass capillary that controlled radial 
alignment6. As shown in Figure 2, the worm first experiences the electric 
field that orients it head-to-tail. Using a direct current, they oriented C. 
elegans locomotion towards the cathode. Then, using fluid flow, a single 
C. elegans animal enters the imaging channel where suction immobilizes 
the worm from above and the capillary attaches to its head7.  
                                                          
5 San-Miguel et al. “Microfluidics as a Tool for C. elegans Research.” WormBook, (2013). 
6  Ardeshiri et al. “A Hybrid Microfluidic Device for On-demand Orientation and Multidirectional Imaging of C. 
elegans Organs and Neurons.” Biomicrofluidics, (2016). 
7  Ardeshiri et al. “A Hybrid Microfluidic Device for On-demand Orientation and Multidirectional Imaging of C. 
elegans Organs and Neurons.” Biomicrofluidics, (2016). 
Figure 2. Schematic representation of a microfluidic chip that uses a glass actuator to 
rotate a single worm7. 
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This novel control technique allows for multidirectional manipulation of 
C. elegans animals. While the research with this microfluidic device 
focuses on imaging of organs and neurons, the control method 
demonstrates great potential for aligning and directing microinjector 
needles into the gonad of a worm.  
1.7.2. Microfluidic immobilization of C. elegans 
There are multiple existing microfluidic technologies that can effectively 
immobilize C. elegans. As seen in the microfluidic chip from Figure 2, 
one method for immobilization is suction. In that chip, once the worm was 
in the correct region, suction across the top of the channel would keep the 
worm in place. Researchers from Wuhan National Laboratory used a 
slightly different method for immobilization that also utilizes suction. 
However, this method, depicted in Figure 3, makes use of a supplementary 
suction in an open chamber8. 
                                                          
8 Zhao et al. “Microfluidic Chip-Based C. elegans Microinjection System for Investigating Cell-Cell 
Communication In Vivo.” Biosensors and Bioinformatics, (2013). 
Figure 3. Microfluidic immobilization of worm head and tail using suction. (B) Worm is 
loaded into immobilization region as its head is suctioned into the first inlet. (C) The worm is 
immobilized when the flailing tail is caught in the second suction chamber. The suction applied to 




As the worm reaches the end of the flow channel, its end is caught by the 
supplementary suction in Figure 3b. Then, after the worm is pushed out of 
the flow channel into the open chamber, the body of the worm is 
immobilized by the main suction and the other end is caught by the second 
supplementary suction as seen in Figure 3c. This suction method 
effectively immobilizes the worm for an external microinjection system to 
inject the worm.  
1.7.3. Microfluidic microinjection of C. elegans 
Also, in 2016, three researchers from the Department of Mechanical 
Engineering at McGill University in Canada developed a microfluidic chip 
that could perform high-speed, automated microinjection of C. elegans. 
This novel device used pneumatic valves to control loading, 
immobilization, and injection. Figure 4 below shows the microinjection 
region of the chip—laminar fluid flow transports a single worm across the 
injection channel, a pneumatic valve pins the worm in place, a needle 
enters through the injection channel, the needle injects the worm, and then 
the immobilization valve is released, allowing fluid flow to transport the 
worm out of the microinjection region. 
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 In a proof of concept experiment, researchers injected 200 C. elegans 
animals, obtaining an average injection rate of 6.6 worms per minute. 
They obtained a pre-sorting success rate of 77.5% (successfully injected 
worms compared to total number of injected worms). A successful 
injection was obtained if they loaded a single worm into the injection 
chamber and then witnessed the worm body expand with the injection 
itself9. Additionally, they found no statistical difference in lifespan 
between a control population and the injected worm population. However, 
                                                          
9 Song et al. “A Microfluidic Device for Automated, High-Speed Microinjection of Caenorhabditis elegans.” 
Biomicrofluidics, (2016) 
Figure 4. Microinjection of C. elegans animals within a microfluidic chip. (A) Worm brought into 
microinjection chamber utilized positive pressure flow through the flow channel. (B) Worm reaches 
microinjection region and is immobilized against PDMS teeth using a control valve located on top of the 
animal. (C) Microinjection needle (labelled as “pipette tip”) brought into microinjection chamber alongside 
worm. External micromanipulator controls needle tip, targets gonad, and injects worm with desired genetic 
construct. (D) Once injected, worm is released from the immobilizing control valve and moved forward due 




this device lacked any type of worm orientation and they did not inject 
genetic material to test for a successful transformation rate. 
1.8. Critique of current technologies 
In evaluating the state of current microfluidic technology and its applications in 
manipulating and injecting C. elegans, we identified three critical design elements 
we could address with our device: (1) orientation, (2) immobilization, and (3) 
microinjection. 
The first design element we identified was orientation of the worms for 
microinjection. However, we decided not to pursue this area of design 
development for two reasons: (1) many well-developed, microfluidic orientation 
elements already exist and could be easily integrated into any C. elegans 
microfluidic chip, and (2) we intend to create a chip whose high-throughput 
nature could overcome the barrier of only obtaining a successful injection 33.33% 
of the time (the gonad comprises ~33% of the worm’s body cross-section so even 
without orientation, the worm would be in the correct orientation ⅓ of the time). 
The second design element we identified was worm immobilization. We found 
that most microinjection chips utilize immobilization methods that place the 
worms under prolonged and extreme stress. Applying continued stress to the 
worms increases the probability that they die during injection, decreasing 
transformation efficiency. Similarly, complex immobilization strategies decrease 
the throughput of these chips, further decreasing injection efficiency. Therefore, 
we wanted to design an immobilization element that would reduce the amount of 
time the worm was subjected to immobilization stress. 
The third design element that we identified was microinjection itself. The 
majority of microinjector chips utilized external microinjector elements. That is, 
they used a microfluidic chip in conjunction with standard microinjector 
equipment like an inverted microscope, micromanipulator, and injection 
regulator. While these systems were efficient and consistent in their injections, we 
believed that they missed the point of microfluidic technology. Microfluidic 
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technology revolutionizes standard laboratory experiments via miniaturization, 
integration, automation, and its high-throughput nature. Shrinking down the scale 
can vastly increase the experiment rate and decrease costs. We believe that 
previous research missed the mark by simply integrating a microfluidic chip with 
a standard microinjection set-up. Instead, the goal should be to create a 
microfluidic device that can conduct orientation, immobilization, and 
microinjection all on-chip without any external (and expensive) instruments. 
1.9. Project goal 
With our objective to design improved immobilization and microinjection 
elements identified, we formulated our project objective: 
Design a microfluidic device to conduct on-chip immobilization and 
microinjection of C. elegans without the aid of any external elements. Our chip 
will increase microinjection efficiency, consistency, and accessibility to 
researchers of all experience levels to advance genetics research and genetic 
engineering technology in C. elegans. 
1.10. Back-up plan 
In the event that we were unable to complete our project by the end of the year, 
we developed a number of back-up plans. 
(1) If we were unable to produce and test a chip that could inject worms, we 
would at least create a novel design for an on-chip microinjector that could 
be easily integrated with existing immobilization and orientation elements 
from other devices.  
(2) If we were unable to complete back-up plan (1), we would at least attempt 
microinjection using the external microinjection elements that we 





1.11. Project significance 
In the rapidly expanding field of genetics and genetic engineering research, the 
manual microinjection process presents a significant rate limiting step. Compared 
to manual microinjection, a high-throughput, self-contained microfluidic chip 
could increase the rate of successful C. elegans microinjections, increase the 
number of researchers able to conduct injections, and reduce the cost of injections 
(fewer startup costs for inverted microscopes, micromanipulators, etc). This 
technology has the potential to dramatically empower C. elegans laboratories 
around the world to conduct human-relevant genetics research and optimization of 




2. Chapter 2: Microfluidic Chip Design and Fabrication 
2.1. Introduction 
The goal of the microfluidic chip is to assist in the microinjection process by 
immobilizing and orienting worms prior to microinjection. The chip accomplishes 
this goal using a variety of regions and microfluidic valves.  
2.2. Key constraints 
Constraints were introduced in two forms: those from the utilized lab spaces, and 
those imposed by the microfluidic chip itself. Two main lab spaces were used, the 
Center for Nanostructures (CNS) and Dr. Emre Araci’s microfluidics lab at SCU. 
Regarding the CNS, the primary constraint was a 2:1 resolution ratio of feature 
height to feature width. The height of the primary flow layer needed to be 40 μm 
to allow for the worms, so features could not be less than 20 μm wide.  
2.2.1. Microfluidic lab vacuum system control 
The main constraint of the microfluidic lab was the lack of controllable 
vacuum system. Many chips that were investigated required the use of a 
vacuum system to immobilize worms prior to injection. Therefore, it was 
not possible to use these designs to achieve the immobilization objective.  
Similarly, many chip designs utilized a vacuum system to alter the 
pressure of the channels the worms flow through. In creating negative 
pressure on one side of the worm, the worms would be sucked into smaller 
channel widths than their body dimensions normally allow without 
causing blockages in the chip.  
2.2.2. Flow channel width versus worm mobility 
Flow channel width versus worm mobility needed to be optimized. 
Narrow channels would need to afford very little mobility, ensuring that 
the worms are held in place properly for injection. However, if the 
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channels became too narrow, without the assistance of a vacuum system, 
the worms may get stuck in the chip.  
2.2.3. Microinjector membrane thickness 
The microinjector membrane is optimized to give acceptable levels of 
deflection when under pressure while retaining its ability to grip an 
embedded needle. Current designs afford little membrane deflection in 
favor of holding the needle in the membrane. Making the membrane too 
thick decreases membrane deflection (See Chapter 6) but increases grip 
strength on the needle. Decreasing membrane thickness allows for more 
deflection but less grip of the needle, potentially allowing the needle to 
fall out during injections.  
2.3. Detailed design description 
The microfluidic chip has two layers: a control layer and a flow layer. Worms 
occupy the flow layer, and the control layer determines how fluid flows through 
the chip.  
 
Figure 5. Example AutoCAD design of full microfluidic microinjection chip. Green regions are the flow layer of 
the chip. Red regions are control valves in the control layer of the chip 
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The chip can be broken down into four main regions: the input, the micropillar 
array, the immobilization and injection region, and the outputs. 
2.3.1. Chip input 
Worms are loaded into the chip at the input by drawing them into a small 
plastic tube (200 μm diameter). This tube is then connected to the output 
of a microfluidic cryo tube. The pressure applied to the tube is controlled 
either manually or by using an external pressure source. Input pressure 
determines the flow rate through the chip.  
2.3.2. Micropillar array 
The next region is the micropillar array. The array is designed to separate 
clumps of worms, as well as filter out any debris that may have been 
generated by the worms or transferred from the worm plates. 
Figure 6. AutoCAD design of micropillar array within microfluidic microinjection chip. Micropillars are utilized 
to (1) redistribute entering worms and prevent animal clustering, and (2) filter debris to prevent clogging of upcoming 
narrow flow channels.  
Worms enter the micropillar array in the upper left and exit through the 
lower right. Pillars are 100 μm by 100 μm. The design for the micropillar 
array is loosely based off an existing design by Song et al. (2016), though 
all dimensions were approximated, as we were unable to find exact 
micropillar arrays specified in the source papers10. The entrance to the 
micropillar array is 120 μm wide, whereas the exit is either 100 μm wide. 
                                                          




We optimized this width so that worms will only load into the primary 
flow channel one at a time, making orienting and injecting the worms later 
in the chip easier.  
2.3.3. Immobilization channel 
The third region of the chip is the immobilization section. 
 
Figure 7. AutoCAD design of immobilization region of microfluidic microinjection chip. The red numerically 
labeled features are in the control layer. The green alphabetically labeled features are in the flow layer.  
The section has five main components: the left flow control valve (1), the 
upper immobilization valve (2), the right flow control valve (3), the flow 
channel (A), and the microinjector membrane (B). Details on how this 
section operates can be found in Section 4.3. 
2.3.4. Microinjection region 
The microinjection region is located just below the immobilization region 
of the chip.  
A 





Figure 8. AutoCAD design of microinjector region of microfluidic microinjection chip. The red numerically 
labeled features are in the control layer. The green alphabetically labeled features are in the flow layer.  
The microinjector region has two main features: the microinjector channel 
(B) and the microinjector valve (1). The flow channel is section A.  
2.3.5. Offloading area 
There are two output valves from the offloading area. 
 
Figure 9. AutoCAD design of offloading region of microfluidic microinjection chip. The red numerically labeled 
features are in the control layer. The green alphabetically labeled features are in the flow layer. The input of valve A 










By turning Valve 2 on and Valve 1 off, flow is directed towards Channel 
A. By turning Valve 1 on and valve 2 off flow is directed towards Channel 
B. Depending on the predicted success of the microinjection, the worms 
can be either directed towards one output or another. At the end of the 
outputs for A and B, worms are then collected in tubes outside of the chip. 
2.4. Expected results 
Protocols for mask creation, photolithography, and soft lithography are very well 
established. Masks are created and printed using a user provided AutoCAD file. 
Photolithography results are detailed in all photolithography chemicals’ respective 
data sheets. Soft lithography expected results are largely based off Dr. Araci’s 
extensive knowledge of soft lithography.  
2.5. Materials and methods 
Chips are created via photolithography and soft lithography, and then tested using 
a microfluidic multiplexer.  
 
Figure 10. Overview of photolithography and soft lithography procedures.11 Image adapted from [12]. 
                                                          




Figure above shows the relationship between molds created via photolithography 
(1-3) and chips created from soft lithography (4-6). The processes depicted differ 
from our own in that they lack a control layer, thus only one photomask is used 
instead of our two.  
2.5.1. Photolithography masks 
Mask designs are created using Autodesk’s AutoCAD software. The chips 
were designed to have two layers: flow and control. Masks had space for 
10 total designs, some unique and some identical.  
2.5.2. Photolithography procedure 
Photolithography is completed using SU8-2050 for both the control and 
flow layers.  
2.5.2.1. Control layer 
Control layers are made to be 50 μm tall using the following 
procedure: 
1. Spin SU8-2050 at 3100 RPM for 30 seconds 
2. Soft bake for 3 minutes at 95°C 
3. Expose for 15 seconds 
4. Post-exposure bake at 95°C for 4 minutes 
5. Develop for 2 minutes 30 seconds in SU8 developer 
6. Hard bake using the following parameters: start at 65°C, 
end at 160°C, ramp up temperature at 120°C/hour, stop 
after 2 hours 
2.5.2.2. Flow layer 
Flow layers are 30 μm tall and manufactured via the following 
protocol: 
1. Spin SU8-2050 at 5000 RPM for 45 seconds 
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2. Soft bake for 5 minutes at 95°C 
3. Expose for 11 seconds 
4. Post-exposure bake at 95°C for 3 minutes 
5. Develop for 2 minutes 30 seconds in SU8 developer 
6. Hard bake using the following parameters: start at 65°C, 
end at 160°C, ramp up temperature at 120°C/hour, stop 
after 2 hours 
2.5.3. Soft lithography procedure 
Soft lithography is created using PDMS.  
2.5.3.1. Control layer 
The control layer is made of 5:1 PDMS to curing agent. PDMS is 
poured over the control mold and then degassed. After curing for 1 
hour at 80°C, PDMS is separated from the control mold, cut into 
individual chips, and hole punched in appropriate locations.  
2.5.3.2. Flow layer 
The flow layer is made of 20:1 PDMS to curing agent. The flow 
layer mold is placed in the spin coater, PDMS is poured onto the 
center of the wafer and spun at 1400 RPM for 1 minute and 15 
seconds. PDMS height should be 50 μm. The mold is cured for one 
hour at 80°C. 
After preparing the layers, the control layer chips are aligned over the flow 
layer mold using a microscope. Control channels must be facing down 
towards the PDMS of the flow layer. The final assembly is then put back 
in the oven to cure for 2+ hours at 80°C. The final chip assembly is then 





2.5.4. Plasma bonding treatment  
Aligned chips must be plasma bonded to a glass substrate prior to testing. 
Using a plasma machine, chips and glass substrate are exposed to plasma 
for 30 seconds, and then treated surfaces are immediately sandwiched 
together. Successful bonding results in an inability to separate the PDMS 
chips from glass substrate. 
2.5.5. Microfluidic multiplexer  
Microfluidic function is controlled using a Microfluidic Multiplexer linked 
to Elveflow software.  
2.6. Results and discussion 
Successful completion of chip fabrication is evaluated using three main criteria: 
layer alignment, presence of sensitive features, and presence of channel collapse. 
Successfully created chips are properly aligned, have all the required sensitive 
features, and no channel collapse. Evaluations of this criteria is done using 
qualitative observations.  
2.6.1. Layer alignment 
Alignment is primarily judged off how the microinjector region valves 
overlay on the microinjector flow channel.  
 
Figure 11. Flow and control layer microinjector region alignment. (Left) AutoCAD design showing proposed 
alignment of control layer (red) on top of flow layer (green) within the chip microinjector region. (Right) Actual 
alignment of control and flow layers within chip. 
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Figure 11 shows an example of successful alignment. Valves are below 
center of flow region (green), and lowermost completely covers thin 
membrane / teeth.  
2.6.2. Sensitive features 
The microinjector teeth / membrane area of our chips is the most sensitive 
in that they are the most difficult to fabricate. Due to constraints of 
photolithography, feature dimensions with an aspect ratio greater than 2 
(feature height to feature width) are difficult to fabricate. Current 
protocols call for teeth dimensions that are 35 micron tall by 20 micron 
wide (aspect ratio of 1.75), which is at the limit of our aspect ratio (2). 
 
Figure 12. Test-filling flow layer of microinjector region with red dye. (Left) Flow layer of microinjector region 
prior to filling with fluid. (Right) Microinjector region filled with red dye (shown in grayscale). 
Figure 12 shows an instance of failed photolithography.  The teeth appear 
to present on the left, but fluid reveals that it can flow right over them. The 
likely cause is that the developer did not wash all unexposed SU8 out of 
the teeth holes, reducing their height and preventing the teeth from plasma 
bonding to glass substrate. Chips with thin, continuous membranes do not 
see this failure, as it is easier to wash out undeveloped SU8. In our final 
design, only chips with thin membranes are used.  
2.6.3. Channel collapse 
Channel collapse results in the permanent sealing or collapsing of a 





Figure 13. Image depicting extreme collapse of microinjector control valve. Valve is collapsed on top of needle 
tip embedded in membrane located between microinjection region and worm flow channel. Valve is collapsed as it is 
permanently plasma bonded to the floor of the flow layer. 
Figure 13 shown above depicts an extreme case of microinjector valve 
collapse. Valve collapse can result from a valve being too large to support. 
The valve is 1000 μm wide but only 30 μm tall, with no support in the 
middle to keep the “roof” from falling down. Collapse may also result 
from pressing on the control channels during plasma bonding, resulting in 
their collapse and bonding to the glass substrate.  
 
Figure 14. Reversibility of collapsed microinjection control valves under extreme pressure. (Left) Collapsed 
microinjector valve before application of pressure. (Right) Restored, non-collapsed microinjector valve after extreme 
pressure was applied to flow layer of microinjection region. 
Figure 14 above indicates that in some cases, valve collapse can be 
reversed by applying extreme pressure to the collapsed valve from the 
flow layer. Collapse is seen in the left image and eventually removed, as 
evidenced by the right image. Despite collapse, all chips were found to 
function.   
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3. Chapter 3: C. elegans preparation and loading 
3.1. Introduction 
In order to test the functionality of the microfluidic microinjection chip, a 
synchronized population of C. elegans is necessary for testing. Worms must be at 
the young adult stage (between L4 and adult) for successful microinjection of 
genetic material12. These worms are then prepared and loaded into the 
microfluidic chip at an acceptable concentration to ensure an even distribution 
throughout the chip. 
3.2. Key constraints 
Key constraints include:  
1. maintaining a population of synchronized C. elegans hermaphrodites at 
the young adult stage,  
2. using the correct buffer solution (M9) to ensure that worms survive 
moving through the microfluidic chip, and 
3. loading the worms into the chip at an acceptable concentration to prevent 
clogging. 
3.2.1. Constraint: Synchronized C. elegans population 
A synchronized population of N2 hermaphrodites was needed for 
microinjection to ensure: 
(1) worms were the optimal stage for effective microinjection of 
genetic material, and 
(2) there was consistency of worm length and diameter for 
optimizing chip dimensions. 
                                                          
12 Evans et al. “Transformation and microinjection.” WormBook, (2006). 
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(1) For optimal microinjection and creation of a successful transformant, 
worms must be healthy, young adult hermaphrodites with a limited 
number of eggs13. See Figure 15 below for details regarding the relative 
ages and reproductive stages if the C. elegans life cycle. At this age, the 
worms are at the right reproductive stage for an injection to puncture and 
flood the distal tip of the worm gonad with the desired genetic construct 
(See Section 1.5: Figure 1 for more detail). This generates transformants 
when the newly forming oocytes encapsulate the injected genetic material. 
 
Figure 15. Life cycle of C. elegans. Life cycle schematic shows four larval stages of C. 
elegans (L1-L4), the temporary, hibernative-like dauer stage, and the reproductive adult 
stage. Time between life cycle stages at 23℃ is listed adjacent to transition arrows. 
Diagram depicts relative sizes of each worm stage with young adults reaching a length of 
1 mm and a width of 35-50µm. Reproductive adults are at the correct stage for 
microinjection. Image from Wolkow et al (2015)14. 
                                                          
13 Evans et al. “Transformation and microinjection.” WormBook, (2006). 




(2) Creation of a population of synchronized worms ensures that all 
worms in the chip have relatively consistent dimensions. This consistency 
is critical to optimize the microfluidic chip channel dimensions to allow 
for: (i) smooth worm flow through channels, and (ii) effective worm 
immobilization. For example, utilizing younger, and thus smaller, worms 
like L1 larvae (see Figure 15) could prevent control valves from 
effectively pinning down the worms for immobilization. The control 
valves might also be unable to prevent worms from escaping under 
actuated control valves. Additionally, older and larger worms might clog 
the chip channels. 
3.2.2. Constraint: Maintaining C. elegans inside the chip 
The worms must be suspended in a fluid to be loaded into the microfluidic 
chip and pushed through the chip’s channels. In the lab, the worms are 
generally grown on Nematode Growth Medium (NGM) agar plates 
covered in a lawn of E. coli (OP50) bacteria15. The worms must be washed 
off these plates and into an M9 buffer solution before they can be inserted 
into the chip. Although the M9 solution does not contain a food source, 
the worms can survive in solution for a few hours while the experiment is 
in progress.  
3.2.3. Constraint: Loading worms at acceptable concentration 
When preparing to load the chip for microinjection, the worms must be 
washed off of their NGM agar plate and into a 1.5 ml tube. The number of 
worms per plate is fairly consistent within each population, therefore it is 
important to wash off the worms in the same amount of M9 buffer to 
ensure a relatively consistent concentration of worms. If the concentration 
of worms gets too high, the worms will flood the micropillar array and 
                                                          
15 Stiernagle et al. “Maintenance of C. elegans.” WormBook, (2006).  
27 
 
clog the chip’s channels. See Figure 16 below for an example of an 
acceptable worm concentration within the chip tubing. 
 
Figure 16. C. elegans inside of microfluidic chip tubing. Worms are at the young adult 
stage and are suspended in M9 buffer solution. Loaded into 200 µm diameter plastic tubing 
for insertion into microfluidic inlet ports. 
3.3. Detailed design description 
3.3.1. C. elegans maintenance 
For our experiments, we used a strain of wild type C. elegans worms 
called N216 (see Appendix B for details), as they are a common strain that 
is both easy to maintain and fairly robust for chip tests. They have a 
generation time of roughly 3 days at room temperature (23℃) and a brood 
size of around 350. Worms were grown at room temperature on Nematode 
Growth Media (NGM) agar plates spread with a lawn of OP50 E. coli (See 
Appendix C for NGM plate protocol details).  
3.3.2. C. elegans age synchronization 
As stated in Section “3.2.1 Synchronizing C. elegans,” a synchronized 
population on N2 hermaphrodite worms is needed for microinjection 
because (1) it ensures consistency of worm length and diameter for 




optimal chip performance, and (2) worms must be at the young adult stage 
for microinjection of genetic material to be effective. The worms were 
synchronized using a hypochlorite solution procedure. The procedure 
takes gravid N2 hermaphrodites and immerses them in a hypochlorite 
solution to kill the adults while leaving behind the eggs (which are bleach 
resistant). These eggs are allowed to hatch in media without food. Starved 
L1 larvae will arrest until fed. Upon introduction of food, these larvae will 
resume development from the same point, resulting in a synchronized 
worm population. This process was repeated prior to each chip test to 
ensure consistency of worm age and size. Waiting 3 days after 
synchronization yielded worms at the desired young adult stage.  
3.3.3. Loading C. elegans into chip 
When an NGM agar plate covered in young adult hermaphrodite worms is 
ready for injection, the plate is washed with 1.0 mL of a worm-compatible 
solution called M9 buffer (an anesthetic such as levamisole can be added 
to M9 buffer if desired). Using the same 1.0 mL of fluid, the plate is rinsed 
3-4 times before transferring the worm-containing solution into a 1.5 mL 
centrifuge tube. To load the worms into the chip itself, the inlet tubing is 
attached to a syringe and first filled with the worm-containing solution, 
then loaded with pure M9 buffer. When the inlet tubing is connected to the 
chip, this allows the pure M9 buffer to flush the channels before the 
worms begin to enter. 
3.4. Results and discussion 
For all chip tests, worms were maintained in large, synchronized populations. 
Chip tests were conducted using young adult hermaphrodites. To load the worms 
into the chip, they were washed off their NGM plates in M9 buffer, pulled into 
microfluidic tubing using a syringe, and then inserted into the chip via its inlet 
ports. Analogous to this loading procedure, the worms must be removed from the 
chip post-injection. (See Appendix D for a subset of experiments that attempted to 
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utilize a magnetic levitating cell-sorter by LevitasBio to sort living versus dead 
worms exiting the chip outlet). Outlet tubing was allowed to drip M9 buffer + 
worm solution freely onto NGM plates (without E. coli food source). The liquid 
was allowed to dry before the live worms were picked and moved to a new NGM 
plate with E. coli food.  
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4. Chapter 4: C. elegans Immobilization  
4.1. Introduction 
Prior to microinjection, the worm must be properly immobilized. Failure to 
properly immobilize the worm makes targeting the gonad nearly impossible. 
Additionally, improper immobilization increases the probability that the 
microinjection needle will tear and kill the worm. Thus, it is paramount that the 
worm’s motion through the chip is highly controlled and that it is completely 
immobilized for injection.  
4.2. Key constraints 
4.2.1. Cannot use negative pressure system controls 
Our chip does not use negative pressure system controls. Most 
microfluidic chips achieve microinjection through negative control 
systems to immobilize worms. Negative control systems allow worms to 
get sucked into smaller channels or get stuck against walls with gaps to 
immobilize the worms. The microfluidic lab that we worked in did not 
have these control systems. Therefore, in an effort to keep our project 
accessible to as many labs as possible, we avoided using such systems.  
4.2.2. Only using positive pressure system controls 
Positive pressure controls are the most widely available pressure control 
systems in microfluidics. Our project therefore aims to achieve 
immobilization using only positive pressure control valves. Enough 
pressure on a control valve should be sufficient to immobilize a worm on 
or against a microinjection needle17.  
 
                                                          
17Ardeshiri et al. "A hybrid microfluidic device for on-demand orientation and multidirectional imaging of C. 
elegans organs and neurons." Biomicrofluidics (2016). 
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4.3. Proposed analysis and expected results 
4.3.1. Immobilized worm motion measurements 
Success of immobilization is frequently measured by examining how 
much motion is seen in the worm. Measurements are frequently taken in 
the x-axis (how much the worm moves left and right in the above image), 
and the y-axis (how much the worm moves up and down in the above 
image). Measurements magnitudes are taken in the micron scale. 
4.3.2. Anticipated results 
Current chip design only immobilizes the mid-section of the worm, where 
the gonad is located. The immobilization valve (2) is not the entire length 
of the worm. We therefore expect to see significant movement around the 
head and tail region of the worm, and hopefully very little movement in 
the middle of the worm while it is pressed against the membrane.  
4.4. Back-up plan 
Failure to immobilize will result in fewer successful transformants. If 
immobilization fails, microinjection can still be performed, but the ability to hit 
the gonad with a ~30% success rate will be diminished. As such, researchers will 
spend more time attempting to get a successful injection, though even with a 
reduced success rate throughput should still allow for more successful injections 
per unit time than traditional methods.  
4.5. Materials and methods 
 The immobilization section of the chip has two main units, the left, upper, and 




Figure 17. AutoCAD schematic showing flow and control layer design in immobilization region. The red 
numerically labeled features are in the control layer. The green alphabetically labeled features are in the flow layer. 
The immobilization section has five main components: the left flow control valve (1), the upper immobilization valve 
(2), the right flow control valve (3), the flow channel (A), and the microinjector membrane (B). 
The rightmost valve (3) is pressurized so that liquid can flow past the valve, but 
the worm cannot. Once a worm has reached this valve, the leftmost valve (1) is 
sealed to prevent an additional worm from entering the area. The upper valve (2) 
is then used to immobilize the worm by pressing it against the membrane (B). At 
this point, the worm is at its most immobilized, and is ready for injection. After 
injection, the upper immobilization valve (2) releases the worm from the 
membrane, and the rightmost valve (3) releases to let the worm exit the chip. The 
leftmost valve (1) is then opened again to allow for a new worm to enter the chip. 
4.6. Results 
Figure 18 below shows an adult worm before and after actuation of the upper 
immobilization valve. These results suggest that immobilization using positive 
pressure is relatively successful—post-valve actuation, the worm’s body is 
completely straight and pinned. The worm is incapable of any significant body 
movement. However, immobilization using this method did show considerable 
movement in the head (right) region of the worm. This method also showed that 
the worm could be effectively immobilized between just two valves. In the above 
A 




figure, the teeth are not functioning. As discussed in Section 2.6.2, improper 
photolithography made the teeth shorter and failed to plasma bond.  
 
Figure 18. Immobilization of C. elegans worms utilizing actuated control valve. (Left) Worm pre-immobilization 
shown locked into microinjection region of chip. Control valves on either end of the worm (valves 1 and 3 are out of 
view) are actuated to keep worm floating within microinjection region. (Right) Worm post-immobilization. Worm is 
pressed against PDMS teeth (B) separating the worm flow channel from the microinjection region chamber. An 
actuated control valve located directly on top of the worm (valve 2) is actuated to press the worm down and into the 
teeth. Lower microinjector valve (See Section 2.3.4) also actuated. Numbers and letters correspond to AutoCAD 
drawing shown in Figure 17. 
 
4.7. Discussion 
Qualitative observations of immobilization suggest success regardless of teeth 
presence. Immobilization was seen along the body of the worm, and not in areas 
unaffected by valve actuation. Current observations are not conducive to 
gathering quantitative data. Generating data about average movement ability is 
made more difficult with the low resolution of microfluidic microscopes. Data 
may be changed into qualitative movement data (did the worm move enough to be 










1. Chapter 5: Microfluidic Microinjection of C. elegans 
5.1. Introduction 
To design a microfluidic microinjection device without external components, we 
needed to develop a novel, on-chip microinjection apparatus. To do this we 
embedded a portion of a microinjection needle into a PDMS membrane within the 
chip (Figure 19) that could inject an immobilized worm within the chip’s flow 
channel (Figure 19C). By filling the microinjection region with a genetic 
construct and then pressurizing the chamber, the needle + membrane would 
deflect into the worm and fluid would be injected into the worm. Additionally, by 
pressurizing the control valve located directly above the worm, the worm would 
be simultaneously immobilized against the thin membrane and pushed into the 
fluid-ejecting needle. See Figure 19 below for the concept schematic of our novel, 
on-chip microinjector. 
Figure 19. Concept design for novel, on-chip microinjection chamber. (A) Embedded needle tip in membrane 
separating microinjection region (filled with genetic construct) and worm channel. (B) Microinjection region 
pressurized to deflect needle and expel fluid. (C) Schematic showing embedded needle alongside worm. (D) Actual 




We were able to establish proof of concept for our novel microinjection chamber 
by successfully injecting red dye into a worm. 
5.2. Key constraints 
In order to create a novel, optimized microinjection apparatus, we needed to 
address the following six constraints: 
1. Needle tips must be pulled consistently. 
2. Needle tips must be broken correctly and consistently prior to embedding. 
3. Needles must be inserted deeply enough into the PDMS membrane to 
ensure needle security but not so deeply that worms are accidentally 
impaled in the flow channel. 
4. PDMS membrane thickness must be optimized to ensure good needle 
security and stability without compromising membrane deflection. 
5. Pressure optimization in the microinjector chamber must ensure that the 
correct volume of liquid (and eventually DNA reagent) is expelled from 
the needle in the correct amount of time.  
6. The immobilization valves must be able to hold the worm in place while 
needle is deflected into the gonad. 
5.3. Detailed design description 
5.3.1. Needle preparation and insertion into membrane 
5.3.1.1. Pulling microneedles from glass capillaries 
Two microneedles are pulled from one 1 mm diameter borosilicate 
glass capillaries (Kwik-Fil Item#1B100F-4). Two microneedles are 
made using the Flaming / Brown Micropipette Puller Model P-87 
and the following parameters: Heat: 600, Pull: 40, Velocity: 55, 
Time: 130, Pressure: 500. See below for image of Micropipette 
Puller pulling 2 microinjection needles from a single capillary. 
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Figure 20. Brown Micropipette Puller pulling two glass microinjection needles.  (A) Heating element glowing 
orange as it heats the glass borosilicate capillary pre-pull. (B) Post-pull microinjection needles. 
To ensure that the needle tips are identical, the glass borosilicate 
capillary must be carefully centered in the micropipette puller and 
secured using the knobs shown in Figure 20 shown above. If done 
correctly, one glass capillary will yield two virtually identical 
microinjection needle tips. Note that glass pulling generally 
produces needles whose tips are sealed or melted shut. The tips 
must be broken before being used for microinjection. 
5.3.1.2. Breaking sealed needle tip 
Sealed microneedle tips must be broken prior to insertion in the 
chip or they will not be able to inject fluid into the worms.  
1. Place a drop of halocarbon oil on a glass microscope slide. 
2. Place a coverslip over the drop of oil and allow oil to 
spread past the edge of the coverslip.  
3. Place prepared slide on microscope stage. 
4. Attach microneedle to micromanipulator. 
5. Drag needle tip along the edge of the coverslip until the 
needle breaks. The user should see oil flow into the needle 
tip. Alternatively, the needle can be preloaded with fluid 
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and the user can test whether the needle is appropriately 
broken by attempting to eject liquid (this is the method 
utilized in standard, manual microinjection). This is shown 
in below in Figure 21D. 
6. Remove needle from the micromanipulator and store. 
 See Figure 21 below for visual depiction of tip breaking procedure. 
Figure 21. Breaking of glass microinjection tip to allow fluid flow. (A) Halocarbon oil drop on 
glass slide. (B) Place coverslip over oil droplet. (C) Lightly drag the sealed glass needle tip against 
the coverslip edge. (D) Barely break the needle tip to allow fluid flow. 
5.3.1.3. Cutting needle tip fragments for on-chip injection 
Unsealed needle tips must be broken (see section 5.3.1.2 above) so 
that embedded needle tips can eject liquid inside of the chip. 
1. Place 0.5” by 0.5” chunk of 5:1 (pre-polymer: crosslinker) fully 
cured PDMS on a glass slide. 
2. Set freshly broken needle with tip resting on PDMS chunk and 
tape down base-end of needle to slide (Figure 22 A, B). 
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3. Overlay 0.5” by 0.5” chunk of fully cured, 300 μm thick, 10:1 
(pre-polymer: crosslinker) PDMS on top of the 5:1 PDMS 
chunk. Gently tamp down 10:1 PDMS layer to ensure contact on 
either side of needle tip (Figure 22 C). 
4. Cut microneedle tip to desired size using a razor blade. Cut 
perpendicular to the needle all the way through both PDMS 
layers to ensure needle fragment remains intact (Figure 22 D, E). 
5. Using tweezers, remove the top 10:1 layer of PDMS, checking 
carefully to see which layer of PDMS the needle fragment has 
adhered to. Move the PDMS chunk + needle fragment to a scope 
with needle/micromanipulator attachment. 
6. Attach a fresh, unbroken “guide” needle to the 
micromanipulator. Guide the fresh needle into the back of the 
needle fragment to pick it up. 
Figure 22. Cutting needle tip fragments used for on-chip microinjection. (A) Place freshly broken needle with tip 
resting on 1:5 chunk of PDMS. (B-C) Tape down needle base and place thin (300um) layer of 10:1 PDMS on top of 
needle tip. (D) Use a razor blade to manually cut straight down (perpendicular to the needle tip) through both PDMS 
layers to break off desired needle tip length. (E-F) Separate PDMS chunks containing needle fragment, peel off 10:1 
PDMS layer to reveal tip fragment, and insert fresh “guide” needle into base of needle fragment to pick it up. 
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5.3.1.4. Embedding needle fragments into membrane of microinjector 
chamber 
With the broken needle tip securely resting on the guide needle tip, 
the guide needle can be used to bury the broken needle tip into the 
PDMS membrane separating the microinjector chamber and the 
worm flow channel (Figure 23). To do this, the PDMS chip (flow 
+ control layer) must be placed upside down so that the needle pair 
can reach inside the chip to the membrane of interest.  
Once the needle tip has been embedded in the membrane, tension 
must be placed on the tip so that the guide needle can slide out and 
be removed. This is accomplished by laying a ~100 um protective 
piece of 10:1 PDMS on top of the microinjector region and then 
pressing down gently on the needle tip through the protective 
PDMS. (Note: Without the protective PDMS layer, pressing on the 
needle tip will either shatter the glass or slide the tip out of the 
membrane.) While pressing down gently on the needle tip, the 
guide needle can be retracted and then the protective PDMS layer 
can be removed. Note that it is easier to slide out the guide needle 
if you take care not to jam the guide needle into the broken tip 
when you first pick it up. To finalize the chip, the PDMS chip + 
embedded needle must be plasma bonded to a glass slide to seal 
the microinjection chamber. See figure below for a visual 
description of the needle embedding process. 
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Figure 23. Embedding needle tip fragment into thin membrane of microinjector region. (Left) Schematic of 
using “guide” needle to insert needle fragment into thin membrane. (Right) Top-down view of microinjector region 
with embedded needle fragment after the guide needle has been retracted. 
5.3.1.5. Needle tip flow testing 
With the needle tip firmly lodged in the membrane separating the 
microinjection region and the worm’s flow channel, we needed to 
test whether pressurizing the microinjection region would eject 
fluid from the needle. Preliminary results showed that red food dye 
can be successfully expelled through the needle at a pressure range 
of 15-30 psi. Additionally, even at very high pressures, the dye was 
ejected only through the needle tip and did not leak around the 
base of the needle tip. See Figure 24 below to see ejection of red 
food dye through the needle at 20 psi.  
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Figure 24. Ejection of red food dye through embedded microneedle tip. (Left) Image taken prior to pressurization 
of the microinjection region. White area around needle indicates that the control valve located on top of the 
microinjection region is actuated. (Right) Post-pressurization of the microinjection region at 20 psi. Control valve on 
top of microinjection region is no longer deflected because of the equal pressure between the microinjection region 
and control valve.   
5.4. Results  
With needle tips firmly embedded in the microinjector membrane and proof that 
liquid ejection was possible, we attempted preliminary microinjection attempts 
with a synchronized worm population. Unfortunately, our worm population was 
too old (worms had fully developed oocytes), however, we were able to 
successfully inject 10 worms with red food dye using our novel microinjection 
apparatus. See Figure 25 below to see the before and after of a successful 




Figure 25. Injection of red dye into C. elegans using novel on-chip microinjector. (A) Pre-injection. Adult worm 
trapped in microinjector region with valves on either side actuated. (B) Mid-Injection. Control valve located directly 
on top of worm is actuated to immobilize and press worm into the fluid-ejecting needle tip.  (C) Post-injection. Red 
dye can be seen inside of worm body surrounding the developed oocytes. 
To inject, we used the following procedure: 
1. Load worm into microinjector chamber and trap it by actuating the control 
valves located near its head and tail. 
2. Test the microinjector by pressurizing the microinjection region until a red 
plume appears beneath the worm.  
3. While ejecting dye, actuate the control valve located on top of the worm in 
the flow channel to immobilize and press the worm into the fluid-ejecting 
needle tip. 
4. While still ejecting fluid, de-pressurize the control valve that is 
immobilizing the worm to allow the worm to slide off the needle. 
5. As the worm slides off the needle, red dye seeps into its body, likely due 
to the slight negative pressure created inside the worm during the injection 
procedure. 
5.5. Discussion 
Preliminary injection results are promising and serve as a proof of concept for our 
novel, on-chip microinjector. However, the system we have designed is quite 
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complex and it requires additional validation steps. Some of the aspects of our 
design that require further optimization and analysis are: 
(1) Pressurization of the microinjection region and how it affects membrane 
deflection versus fluid ejection. By coupling the processes of needle 
deflection and fluid ejection, we have created a mathematically complex 
problem to solve.  
(2) Actuation of the control valve located on top of the microinjection region. 
It has the potential to alter the angle as well as the fluid-ejection capacity 
of the needle that protrudes into the worm flow channel.  
(3) Worm survival rate post-injection. We need to analyze how this 
immobilization + compression-injection affects worm lifespan. 






6. Chapter 6: Chip Validation - COMSOL Simulation of 
Microinjector Region 
6.1. Introduction 
To predict whether the thin membrane + embedded microneedle would be able to 
deflect enough to microinject and to visualize the effect of a pressurized valve on 
embedded needle movement, we needed to conduct simulations using COMSOL. 
COMSOL, a multiphysics software, uses finite element analysis to provide a 
model and simulation system. To obtain a range of membrane deflection values, 
the microinjection region was modeled in COMSOL. In COMSOL, parameters 
such as pressure and membrane thickness, can be swept over a range to predict 
the resultant deflection outputs. Then, in order to visualize the embedded needle 
movement, a side-view cross section of the chip was modeled in COMSOL. 
Varying the pressure of surrounding chambers can provide valuable insight as to 
how the needle will react when we pressurize the chambers in our chip. 
6.2. Key constraints 
The membrane deflection range and behavior of the embedded needle are 
constrained to the multiphysics software of COMSOL. While COMSOL provides 
the tools to model the deflections associated with the microinjection region of the 
chip and the pressurized chambers effect on the movement of an embedded 
needle, it is only a theoretical simulation. The physical microinjection chamber 
and embedded needle will not necessarily behave according to the ideal 
conditions of the simulation. Additionally, the movements and reactions of C. 
elegans animals are not fully predictable. 
6.3. Detailed design description 
6.3.1. Microinjection region for membrane deflection simulation 
The microinjection region of the chip can be modeled simply by using an 
assortment of blocks with dimensions matching the chip. The model, as 
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seen in Figure 26, consists of six total blocks to create a glass base, walls 
surrounding an open chamber, and a thin membrane to top the chamber. In 
the physical chip, however, there is no glass base backing the chamber, so 
the sturdy properties of glass are used to mimic the thick PDMS base 
relative to the thin membrane.  
 
COMSOL allows model parts to be hidden to show interior structures. 
Figure 27 shows the highlighted chamber once the glass base has been 
hidden.  
Figure 26. COMSOL model of microfluidic microinjection region based on a glass model. 
The fully constructed COMSOL model of the microinjection region for our chip. The top-most 
surface is the thin membrane between the microinjection chamber and the worm flow channel. 
Figure 27. COMSOL model of microinjection region chamber. Inner chamber of the 





To simulate the bonded nature of the chip, once created, the blocks were 
mated. This mating was important to simulate the fully bonded chip. The 
model now functions as a single unit. To distinguish the glass base from 
the PDMS, materials were assigned to blocks. The PDMS has a Young’s 
modulus of 1000 kPa, a Poisson’s ratio equal to 0.49, and a density of 
1000 kg/m3. The glass only increases in the Young’s modulus value from 
1000 kPa to 1000 MPa. 
6.3.2. Embedded needle for needle movement simulation 
To simplify the model of needle movement, COMSOL was used to model 
the side-view cross-section of the chip. As shown in Figure 28, the model 
uses an assortment of rectangles that resemble the chip dimensions.  
Similar to the microinjection region, these rectangles were mated to mimic 
the bonding of the layers. Then, assigning materials helps to distinguish 
the rectangles so that each contributes to a model that more closely 
resembles the true nature of the chip. Using the same material properties 
for the glass and PDMS materials as the three-dimensional microinjection 
chamber model, the base rectangle and the thin rectangle, that appears to 
be a line through another rectangle, are glass. The base rectangle is the 
glass base, and the thin rectangle represents the embedded needle. The 
remaining rectangles are PDMS.  
Figure 28. COMSOL model showing effect of control valve on embedded 
needle movement. Two-dimensional model of the chip used for studying the 
movement of the needle embedded in the thin membrane. 
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6.4. Simulation methods 
6.4.1. Membrane deflection simulation 
Deflection values for the membrane were obtained while varying the 
chamber pressure and the membrane thickness. COMSOL contains a 
function called “parametric sweep” that computes simulations for a range 
of desired values. To use this function, the variables or parameters must 
first be defined. Under the global definitions, we defined pressure and 
membrane thickness as parameters. Then, the set value for these 
parameters must be changed to the parameter name. Once set up, we 
computed the parametric sweep then we evaluated the results for 
maximum deflection. This was done for three models with differing 
membrane thicknesses—1 µm, 50 µm, and 1000 µm. 
6.4.2. Needle movement simulation 
The needle movement simulation is more ambiguous. In theory, the 
microinjection chamber and the valve above this chamber will be 
pressurized over a range of pressure inputs to study the reaction of the 
needle. However, because COMSOL is a multi-physics simulation 
software, certain interactions must be more explicitly defined. At high 
enough pressures in the top chamber, deflection of the membrane will 
touch the needle. This interaction is not defined in COMSOL. Yet, 
COMSOL contains a function called “contact pairing” that can resolve the 
interaction problem between the membrane and the needle. Once the 
surfaces are paired, then the pressure values can be swept to evaluate the 
needle movement. 
6.5. Results and discussion 
6.5.1. Membrane deflection 
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When we computed the parametric sweep that simulated the pressurization 
of the microinjection chamber, we saw clear deflection across the thin 
membrane. This deflection simulation is pictured in Figure 29. 
Once deflection was observed in the model, the simulation was evaluated 
for maximal membrane deflection. For the three different models with 
varying membrane thickness, the maximal deflection was plotted against 
the input boundary load as shown in Figure 30.   
Figure 29. COMSOL model depicting the membrane stress that results from applying a boundary load to 
microinjection chamber. The dark blue areas of the model are not stressed. The light blue and orange areas show 
stress and deflection of the thin membrane. The orange indicates increased stress, revealing maximal stress located in 
the center of the thin membrane 
Figure 30. Graph comparing applied pressure to thin membrane deflection based on COMSOL simulation. The 
maximal deflection of the thin membrane is computed and graphed according to the pressure of the chamber. This was 
computed for models with membranes of varying thickness—1 µm, 50 µm, and 1000 µm. 
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These results gave valuable insight to our observations as we pressurized 
the microinjection region of our chip. Because the source of the behavior 
of the membrane was unclear, isolating the deflection without liquid 
ejection in a simulation allowed us to see the deflection of the membrane 
only as a product of pressurization with no confounding variables. 
6.5.2. Needle movement 
Due to the complexity of simulating the movement of the needle, this is an 
ongoing simulation project. Ideally, these results will give us greater 
insight as to how the pressurization of these chambers affects the behavior 
of the needle in the membrane. 
6.5.3. Discrepancies between simulation and observation 
The results of the simulation are not similar to observations of the system. 
Upon pressurizing the microinjection chamber, very little to no deflection 
is seen, in contrast to the approximately 20 micron deflection that is 
expected, this is likely because this simulation is coupled with a fluid 
ejection model, and the two systems have not been reconciled. Future 





7. Chapter 7: Summary and Conclusion 
7.1. Restatement of project objective 
Our objective was to design a microfluidic device that could conduct on-chip 
immobilization and microinjection of C. elegans without the aid of any external 
elements. Our chip aimed to increase microinjection efficiency, consistency, and 
accessibility to researchers of all experience levels in order to advance genetics 
research and genetic engineering technology in C. elegans. 
7.2. Project accomplishments 
7.2.1. 100% microfluidic device 
Our final device is completely microfluidic. There are no external 
components beyond those required to operate a microfluidic device. Our 
chip can be operated using multiple microscopes such as a basic dissecting 
scope (not just an inverted). The compatibility of our chip allows for 
future full automation via computer vision and programming. Overall, our 
chip is cheap, and easy to use regardless of your experience level.  
7.2.2. Design novelty 
Our chip novelty is the on-chip microinjection apparatus. Without 
cumbersome external elements, our chip is easier to setup and use. 
Additionally, our chip has the potential to unclog clogged needle tips. If 
the worm flow channel is pressurized, fluid is forced backward through 
the needle, expelling clogging debris. The ability to unclog needles saves 
researchers from wasting valuable time and reagents.  
Another novel aspect of our design is its brief worm-immobilization time. 
Compared to other chips and methods, our design immobilizes worms for 
a fraction of the time, reducing unnecessary strain on the worm’s body. 
Worms spend a maximum of 1 second immobilized before being allowed 
to float off the needle and into the channel again. By reducing the total 
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stress exerted on the worm, we increase the likelihood of their survival. 
This increases the number of successful injections and ensures that 
valuable worm strains are not wasted.  
7.3. Future work 
7.3.1. Complete characterization of novel, on-chip microinjector 
The physical properties of the novel, on-chip microinjection apparatus is 
not yet fully understood. Currently, our design utilizes two integrated 
systems, (1) a physical deformation system, and (2) a fluid ejection 
system. This poses a challenging math and physics problem as the 
relationship between chamber pressurization is confounded with both 
membrane deflection and fluid ejection. We are currently conducting 
ejection rate experiments to characterize the needle tips. We are also 
exploring further COMSOL simulations to try to better understand the 
discrepancy between our COMSOL simulation results (see Chapter 6) and 
our failure to observe membrane deflection in our experiments.  
In addition to the issue of the coupled deflection-ejection system, we need 
to fully characterize the effect of actuation of the control valve located 
directly above the microinjection chamber (see Figure 7, red valve below 
valve 2) on the angle of the needle. It is unclear how dramatically the 
valve actuation affects needle angle and whether it has the ability to fully 
stop needle fluid flow when actuated. 
7.3.2. Injection of genetic construct 
Currently, we have been injecting red food dye into the worms to better 
visualize the injection process. Moving forward, we will be injecting a 
clear solution containing our genetic construct. We will be injecting a 
plasmid (rol-6[su1006]) that confers a “roller” phenotype to the worms. 
This means that we will be able to determine transformation efficiency by 
scoring the number of “roller” worms generated by our injections. 
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7.3.3. Post-injection analysis 
Finally, to evaluate the effectiveness of our chip as a tool for C. elegans 
microinjection, we will need to determine (1) transformation efficiency, 
(2) the rate at which worms survive the injection procedure, and (3), the 
effect of our injection technique on worm lifespan. All three of these 
statistics will be obtained once we start regularly injecting synchronized 
populations of young adult worms with our rol-6 plasmid. 
7.4. Engineering standards 
This project addresses multiple engineering concerns: ethics; health and safety; 
manufacturability; usability; science, technology, and society; economic; 
environmental impact; civic engagement; and sustainability. The ethics of this 
project will be examined throughout each subsequent engineering standard. For a 
more thorough and ethics-specific analysis, see Appendix E. 
7.4.1. Health and safety 
All users have a right to their own safety and a similar duty to maintain 
their own and the safety of others. Our product both introduces and 
mitigates risks in comparison to traditional microinjection. While 
mitigation of existing risks is beneficial to all, the introduction of some 
new risks may outweigh whatever mitigation is introduced. The danger 
that any of these risks pose is entirely based on user expertise and 
experience.  
The majority of the new risks that we introduce are the result of the 
additional facilities and equipment that our project requires for fabrication 
(See Section 3.1). Our project calls for the use of chemicals that are 
known to be hazardous (toxic, flammable), and uses a machine that 
requires UV light. Exposure to chemicals can be mitigated by wearing 
proper protective equipment (PPE) and following lab safety protocols, and 
eyes can be protected from UV exposure. However, other exposed areas of 
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the skin (mouth, neck, etc.), cannot be protected from the UV light, and it 
is recommended that the user face away from the machine during 
exposure times.  
Our product fabrication also requires that some microinjection equipment 
be used in untraditional ways. The micromanipulator and inverted 
microscope are used to break micron scale glass needle tips from 
traditional microinjection needles. While protocols have been created to 
diminish the risks and handling of these micron size needle fragments, 
always consult with the owner of the equipment before using it as our 
product requires. PPE should always be worn to avoid fragment contact 
with the skin, and eyewear is essential to avoid getting fragments in the 
user’s eyes. 
No injuries have occurred over the course of this project while completing 
any procedures. Despite the risks introduced, current safety protocols in 
most lab spaces should be sufficient to mitigate risks and potential harm. 
Overall, the biggest potential risk to a user’s safety is introduced by the 
user alone if she chooses not to follow appropriate PPE guidelines and 
safety training.  
Our product eliminates multiple dangerous elements required by 
traditional microinjection. It no longer requires the user to directly interact 
with glass with molten sections, and our product decreases the need for 
exposed flames in lab. Our product eliminates the requirement of mouth-
pipetting to load genetic material into microinjection needles. While most 
of these genetic materials have little immediate risk to a user’s health, 
mouth pipetting should always be avoided. Our product also reduces the 
probability that a user impales their hand on a needle when loading genetic 
material into a microinjection needle. 
Traditional methods have higher hazard risk than our final solution. Our 
solution introduces new hazards with known safety procedures. Our 
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solution does not require that any used chemicals come into even remote 
contact with the mouth. Traditional microinjection also has a high 
probability of physical injury, via either puncture wounds or burns. It is 
hard to mitigate the probability of these risks, as they are necessarily 
introduced for the sake of traditional microinjection.  
7.4.2. Manufacturability 
Our product requires multiple facilities and a variety of equipment: 
research location determines feasibility of use. If one is already capable of 
conducting C. elegans microinjections, the individual would still require a 
significant amount of resources to be capable of using our product. 
The microfluidics side of our product requires a cleanroom, a microfluidic 
laboratory, and lots of equipment (spin coaters, a mask aligner, volatile 
chemicals, etc.). The product also requires a microfluidic multiplexer, 
multiple air and vacuum sources, and the accompanying software to make 
the multiplexer work. 
Santa Clara University is fortunate to already have all of these facilities 
and materials, no new equipment was purchased to make our device work. 
If a C. elegans researcher find themselves in a similar position, then our 
product will work for them. Current prototypes are capable of injecting 
over twelve worms per use, compared to three injections for traditional 
methods. Our chip also has the unique ability to unclog its needles, saving 
more genetic reagent in comparison to traditional methods. Finally, our 
product can be used under any microscope, freeing microinjection from 
the inverted microscope. Our product saves time, allowing for more 
injections, more experiments, and more research. 
However, while other facilities and universities have access to the required 
spaces, many C. elegans researchers do not. This is a violation of fairness; 
our product can only be used in higher-end research settings. Deciding 
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reparations for this violation is difficult, the common-good approach 
would imply that those with access to our product have a duty to share 
their findings to those without access. In the C. elegans research 
community, people are much more forthcoming with their findings, but 
our product does not diminish the barrier between C. elegans researchers 
with access to higher-end facilities versus those with access to lower-end 
facilities. It is possible that our product could be commercially built, but 
then it would still require a microfluidic multiplexer and software to 
function, neither of which are cheap.  
7.4.3. Usability 
As mentioned in Section 1.2, microinjection is a linchpin to C. elegans 
genetics research. Assuming a researcher can access and use our product, 
she will find this is no longer the case: microinjections can be performed 
by anyone with our product, and they can be performed quickly. Hence, 
we anticipate more publications pertaining to C. elegans and 
microinjection, potentially to the chagrin of established microinjection 
researchers. Overall, though, our product long term benefits outweigh its 
immediate consequences.  
Our product requires one person for complete fabrication. It does not 
require someone with a doctorate, but fabrication of the product relies on 
someone having basic knowledge about microfluidics. Hence, the 
knowledge required to complete microinjection is less severe, but may not 
be found in a traditional C. elegans research laboratory. 
Our product requires two people to operate. Operation of this device is 
very difficult without two people, primarily due to the software that 
interacts with our chip. On a per capita basis, our product requires more 
than traditional methods; however, it also increases opportunities for a 
workforce of undergraduate research students looking for work in labs. 
Allowing undergraduates to participate in the research and assist in 
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operations would also afford the PI more time to examine topics that are 
less familiar to other students. In general, despite the increase in 
personnel, the project as a whole is more accessible to everyone; allowing 
for better division of labor and more rapid progress.  
7.4.4. Science, technology, and society 
Our product is designed to support research in the field of genetic 
engineering, particularly within C. elegans. C. elegans is studied due to 
the high amount of overlap between their genome and humans. Ultimately, 
researchers hope to apply their findings to humans. Genetic engineering in 
humans is a controversial topic: it holds the potential to cure many 
diseases, but at the most extreme of ends could result in the creation of 
“designer babies.” Our product has the potential to bring about either one 
of these ends - society and genetic engineers will have to choose which 
ones we achieve. In order to reach the most desirable of ends, it is 
essential that we continue to talk about genetic engineering, its potential 
impacts, and how we wish to use the technology. This is the best way to 
ensure that our product does not help realize an undesirable future.  
7.4.5. Economic  
The cost of our product is low. Based on raw materials alone, an 
individual chip costs no more than five dollars (PDMS, C. elegans 
maintenance supplies, etc.). It is difficult to account for the costs that our 
equipment incurs, though. We are fortunate in that no additional 
equipment needed to be purchased for our project. The most expensive of 
items (inverted microscope, mask aligner, micromanipulator, clean room) 
already existed on SCU’s campus. If we were to secure our own facilities, 
costs for our product would go up exponentially. Finally, as students, we 
do not charge for labor. In total, about ten hours are required to make a 
chip from scratch (no mold), if a mold is present, six hours are required 
(mold casting and needle embedding). Lots of this labor requires skilled 
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technicians and would drastically increase the cost of our chip. For our 
purposes, our chip is cheap - this may not be the case outside of SCU.  
7.4.6. Environmental impact  
Our product has two primary wastes: sharps and chemicals. Sharps are 
convenient enough to dispose of, our chemical waste is another story. All 
chemicals pertaining to mold fabrication (See Section 2.5) are hazardous 
(toxic, flammable), and require care to be disposed of properly. PDMS 
becomes far less toxic as it cures, eventually becoming biocompatible. 
However, chip fabrication wastes a lot of PDMS. While we have 
attempted to mitigate PDMS waste throughout our project (some is reused 
for the needle cutting procedure), there is still inevitable waste, which 
must be taken into consideration.  
7.4.7. Civic engagement 
There is potential for a patent in our product. Approval for a patent will 
need to be filed through the US patent office. In order to receive a patent, 
we will need to prove that our product does not infringe upon any other 
patents. Similarly, we will need to prove that our product is novel enough 
to warrant receiving its own patent.  
7.4.8. Sustainability 
Our product is more sustainable than traditional methods, though 
microfluidic chips are inherently disposable. Needles clog frequently in 
microinjection due to their small size, but our chip does allow them to be 
unclogged. Therefore, we can get needles to last longer than usual. Chips 
should not be used for multiple genetic constructs, as microinjection 





7.5. Team and management 
For more detailed information related to our project, see Table 1 below for 
relevant contact information. 
Table 1. Team member specialties and contact information. 
 Name Email Discipline Project Expertise 
Team Delaney Gray drgray@scu.edu Bioengineering C. elegans, needle embedding, 
microfluidics/fabrication 
Alex Hadsell ahadsell@scu.edu Bioengineering Microfluidics/fabrication, AutoCAD, stats 
Jessica Talamantes jtalamantes@scu.edu Bioengineering COMSOL simulations, LeviCell  
Advisor Dr. Emre Araci iaraci@scu.edu Bioengineering Microfluidics, microfabrication 
Advisor Dr. Leilani Miller lmiller@scu.edu Biology  C. elegans, manual microinjection 
7.6. Budget 
For general budget information, see Table 2 below. All funds were provided by 
the Santa Clara University School of Engineering. All supplies not listed were 
generously provided by Dr. Emre Araci (SCU Bioengineering Department) and 
Dr. Leilani Miller (SCU Biology Department). 
Table 2. Project budget breakdown. 
Category Item Number Unit Cost ($) Total ($) 
Photolithography supplies 
Silicon wafers (10 cm) 10 wafers 10.00 100.00 
SU-8 2050 1 (500 mL) 650.00 650.00 
SU-8 Developer 1 (4L) 172.90 172.89 
SPR 1 (500 mL) 700.00 700.00 
SPR Developer 1 (1 gallon) 48.75 48.75 
Soft lithography supplies 
PDMS 1 gallon 700.00 700.00 
TMCS 50 ml 120.00 120.00 
C. Elegans supplies 
Bactopeptone 1 (500g) 133.57 133.57 
Agar 1 (500g) 181.98 181.98 
60 mm worm plates 1 case (500) 52.97 52.97 
Glass capillaries 1 box (500) 57.00 57.00 
   Total cost: $2,917.16 
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7.7. Project timeline 
8. Our project was broken down in four main phases which loosely corresponded to the four 
quarters we spent working on this project. We spent the Spring (2018) of junior year 
conducting background research on our project and formulating our initial microfluidic 
chip design. The following three quarters in our senior year were spent designing, 
manufacturing, and testing three different iterations of our chip design. For a general 
overview of our project timeline, see Table 3 below. 
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2. Appendix A: Manual microinjection procedure 
 
Figure 31. Schematic of manual microinjection procedure. (A) Glass slide (light blue) with agarose 
injection pad (gray). (B) Drop of halocarbon oil (yellow) placed on injection pad to act as temporary buffer 
between worm and sticky injection pad. (C-D) Worm manually placed in oil droplet for maneuvering. (E) 
Worm is manually oriented using a modified (heat-blunted) glass Pasteur pipette. Worm is rolled until gonad 
is in proper position for a successful injection. (G) Once aligned, worm is pressed down through the oil to 
contact the adhesive injection pad. (F) With worm securely adhered, a microinjection needle can be brought 




                                               







3. Appendix B: Ordering and maintaining C. elegans N2 strain 
4. C. elegans strains can be ordered from the Caenorhabditis Genetics Center2. The C. 
elegans wild isolate N2 strain was utilized for all chip experiments. C. elegans animals 
are hermaphroditic (although males arise at a rate of < 0.2%) and can self-fertilize a 
brood size of about 3503. Their generation time is temperature-dependent; At 23℃, their 
generation time is about 3 days from egg to egg-laying adult. At 20℃, their generation 
time is about 4 days. At 15℃, their generation time is about 7 days. The N2, wild type 
worms used in these experiments were maintained at 23℃ and allowed to self-fertilize. 
5. Appendix C: Preparation of Nematode Growth Medium (NGM) agar plates 
6. Materials 
● 60 mm non-vented sharp edge petri dishes4 
● PourBoy Sterile Media Dispenser5 
● Magnetic stir bar 
● Magnetic stir plate 
● 2L Erlenmeyer flask 
● Aluminum Foil 
● Autoclave tape 
● Deionized water (Barnstead 10 megaohm) 
● NaCl salt 
● Bacteriological Grade Agar6  
● BD Bacto™ Peptone7 
● 5 mg/ml cholesterol in ethanol 
● 1 M CaCl2 
● 1 M KPO4 
● 1M MgSO4 
                                               
2 https://cgc.umn.edu/ 












● Cholesterol (5mg/ml) 
 
Methods 
▪ In the 2L Erlenmeyer flask combine: 
• 1450 ml diH2O (Barnstead 10 megaohm) 
• 30g Bacteriological Grade Agar  
• 3.75g BD Bacto™ Peptone 
• 4.5g NaCl salt 
▪ Mix with magnetic stir bar. 
▪ Cover mouth of flask with foil, mark with autoclave tape, autoclave on liquid 
cycle (20 minutes). 
▪ Autoclave PourBoy tubing on gravity cycle (10 minutes). 
▪ Place media flask into 65 centigrade water bath and allow to cool for 1 hour. 
▪ While cooling, prepare plate pouring workspace: 
• Clean counters with lysol. 
• 1 flask of media should fill 6-7 sleeves of petri dishes (20 per sleeve). Set 
up petri dishes in stacks of 5. 
• Set up PourBoy sterile media dispenser and spray ethanol on the bracket 
area to sterilize. 
• Set PourBoy to dispense 11-12ml of media per plate. 
▪ Once cooled, add the following salts in order to the autoclaved media: 
• 1.5ml 1 M CaCl2 
• 1.5ml 1M MgSO4 
• 37.5ml 1 M KPO4 
• 1ml Cholesterol (5mg/ml) 
▪ Pouring NGM agar plates: 
• Run one bottle of 50/50 autoclaved diH2O followed by one bottle of 
autoclaved diH2O through the pump system. 
• Carefully place tube into media flask and pump until air bubbles clear and 
NGM agar is flowing smoothly. 
• Pour 11-12 ml of NGM agar into each plate (one pump per plate). 
• Once done, immediately rinse 2L flask and PourBoy tubing with hot water 
to prevent solidification of agar inside. 







▪ Spreading NGM agar plates with E. coli OP50 bacteria food source 
• C. elegans animals are generally maintained monoxenically with an E. coli (OP50) bacterial food 
source. E. coli OP50 is an uracil auxotroph that is growth-restricted by the lack of uracil found in 
NGM agar plate media8. It is spread manually on NGM agar plates and grown as a restricted 
lawn.  
 
Appendix D: Magnetic density-based sorting of C. elegans  
Introduction 
LevitasBio, a local bioengineering company in the Bay Area, created a “Magnetic 
Levitation Technology,” and implemented this novel technology into their device, 
LeviCell. LeviCell consists of two permanent magnets on either side of a flow 
channel. Previously, this device has been used for cell analysis and sorting. When 
cells flow through the channel, the magnet technology generates separation, 
provoking the cells to levitate based on cell type. This observable separation is 
dependent primarily on cell density and is supplemented by the magnetic 
properties of the cells. Further separation occurs as the sample flows into a 
bifurcated tube, allowing for collection of the separated samples. The device 
allows for flow control so, in addition to controlling flow rate, the sample in the 
channel can be held for levitation analysis. 
One of our senior design advisors, Dr. Emre Araci, had been in contact with 
LevitasBio about installing LeviCell on Santa Clara University campus and 
potential research opportunities with the technology. With the novel separation 
technology, we were curious of the potential application in C. elegans sorting—
whether that is sorting worms of different sizes, sorting live worms versus dead 
worms, or some other type of sorting—, rather than cell sorting.  
 
 
                                               







Detailed design description 
With no prior C. elegans exploration in LeviCell, we approached the technology 
from a discovery-based standpoint. We were interested in whether the levitation 
technology would affect C. elegans worms.  
      LeviCell viability 
The LeviCell technology does not rely solely on the permanent magnets 
surrounding the flow channel. Instead, the sample of interest must be 
suspended in a levitation reagent. So, we decided to first test whether the 
C. elegans worms tolerate the reagent. We created two solutions, the first 
using DI water. DI water is commonly used as a buffer solution when 
using LeviCell. However, DI water is known to aggravate C. elegans 
worms. So, we made the other solution using the known worm-compatible 
buffer, M9. Diluting the levitation reagent to a 1X concentration, we 
suspended the C. elegans worms and observed the worms over increments 
of a two-hour time period to assess viability. 
 Preliminary Tests 
Once we proved that the Levitas levitation reagent was not toxic for C. 
elegans, we decided to observe how the LeviCell device affected the 
worms. A few plates of live C. elegans were washed using the M9 buffer, 
and this worm solution was then combined with the levitation reagent to 
create a 1X concentration just as in the viability test. Then, after properly 
preparing and priming the LeviCell device, the sample of worms was 
flowed through the device. 
Control Tests 
After confirming that the LeviCell device affects C. elegans worms, the 
question became whether there were noticeable levitation differences 
between any variation of the worms. For this reason, the worm samples for 







1X concentration solution of levitation reagent and M9 buffer. The first 
sample was a live sample, similar to those from the preliminary tests. The 
second sample consisted of anesthetized worms. The worms were 
anesthetized using the same methods described in Chapter 3 of this paper. 
For the third and final sample, the worms were killed in bleach. This 
process followed the same bleaching process used in the worm 
synchronization described in Chapter 3. Then, after preparing and priming 
the LeviCell device, each sample was again flowed through the device. 
Expected Results 
While cells are relatively small and immobile, adult C. elegans used for genetics 
research are approximately 1 millimeter in length and 40 𝜇m at their largest 
diameter—significantly larger than individual cells. In addition to their size, C. 
elegans animals are extremely mobile and tend to swim against the current of the 
flow. Due to these characteristic differences, we were not sure what to expect 
when introducing C. elegans to LeviCell. We were expecting the magnetic 
levitation technology to affect the C. elegans, but we were not sure to what extent. 
Additionally, the densities of C. elegans worms are unknown, and thus, there was 
a potential for variations in levitation height resulting from any number of 
variables. We considered age as a potential factor. Whether or not the worms 
were alive, dead, or anesthetized was another potential factor. Ultimately, 
however, we did not anticipate significant levitation height differences as there 
does not appear to be a significant difference in worm densities considering the 
controlled variables. 
• Materials and Methods 
o Materials 
▪ Maintained C. elegans plates 
▪ M9 Buffer 
▪ Materials for anesthetizing and bleaching the worms 







o Preparing the Live Sample 
▪ Wash the worm plate using 1 mL M9. 
▪ Transfer 50 µL 20X Levitation reagent into a clean, labeled 1.5 mL 
centrifuge tube. 
▪ Transfer all the M9 solution containing the C. elegans worms into the 
same tube and add M9 until the total volume is 1 mL (some M9 was lost 
while washing the plate). 
o Preparing the Anesthetized Sample 
▪ Follow the method for anesthetizing the C. elegans 
▪ Transfer 50 µL 20X Levitation reagent into a clean, labeled 1.5 mL 
centrifuge tube. 
▪ Transfer the C. elegans solution to the same tube. 
▪ Add M9 until the total volume is 1 mL. 
o Preparing the Dead Sample 
▪ Follow the method for synchronizing the worms. 
▪ Resuspend the dead worms in 0.5 mL M9. 
▪ Transfer 50 µL 20X Levitation reagent into a clean, labeled 1.5 mL 
centrifuge tube. 
▪ Transfer the resuspended C. elegans to the same tube. 
▪ Add M9 until the total volume is 1 mL. 
Results 
The initial viability tests revealed that the levitation buffer is not toxic to C. 
elegans. Additionally, those initial tests confirmed the well-established 
knowledge that a C. elegans prefers M9 buffer to water.  
The preliminary attempt to insert a live, unanesthetized sample into the LeviCell 
device showed that the magnetic levitation technology does, in fact, affect C. 
elegans. As shown in Figure 32, the C. elegans animals are seen levitating in a 
confined band within the flow channel of the LeviCell device. With this 







eggs flowing outside the band, and there were occasional C. elegans, either 
developing or developed, that were not constrained to the band pictured in the 
figure. However, the live C. elegans were seen beyond the band more frequently 
than the eggs. 
 
Figure 32. Live, unanesthetized worms levitating in LeviCell instrument. The agar plate washed 
for this experiment was not synchronized, thus providing the observable age variety from eggs to 
adults. 
The control tests featured the three sample environments—live, unanesthetized C. 
elegans, live, anesthetized C. elegans, and dead worms. The live, unanesthetized 
sample did not deviate from the preliminary test. The live, anesthetized sample, 
seen in Figure 33, showed a similar result. Eggs and anesthetized worms alike 
flowed through the channel in a relatively confined band. The outliers appeared 
less frequently compared to the unanesthetized sample, yet, there were still 
occasional outliers. Notably, the live, anesthetized C. elegans sample band 








Figure 33. Live, anesthetized worms levitating in LeviCell instrument. 
Not surprisingly, the final test, featuring the sample of dead C. elegans showed 
minimal results. Due to the rapid decay of the C. elegans’ organism following a 
bleach treatment, the sample did not contain enough matter for observation. 
Discussion 
Because there is minimal research relating LeviCell use and C. elegans, there are 
many potential avenues for future research. It is known that varying the levitation 
reagent can increase the separation between matters of different densities. 
Additionally, it would be interesting to test the effect of injection on the levitation 
height, and the crossover of the magnetic levitation technology and C. elegans 
needs to be explored. Therefore, because we have proven that the technology 









Appendix E: Ethical Analysis of Microfluidic Chip for Microinjection of C. Elegans 
1.  Introduction  
For our Senior Design Project, we designed a microfluidic device to perform 
microinjection of genetic material into C. elegans, an invaluable model organism. Our 
project objective was to increase microinjection efficiency, consistency, and accessibility 
to researchers of all experience levels in order to advance genetics research and genetic 
engineering technology in C. elegans.  
 1.1 Caenorhabditis elegans is an invaluable model organism 
C. elegans is a terrestrial soil nematode that has served as a model system for 
human disease and genetics research since the 1970’s. The worm is an invaluable 
model organism for the study of molecular and cellular processes in humans due 
to their small size, rapid generation time, easy cultivation, and invariant cell 
number. Additionally, 40% of genes known to be associated with human disease 
have clear orthologs in the C. elegans genome.  
 1.2 Limitations of traditional microinjection methods 
In C. elegans genetics research, microinjection of genetic material into the worms 
is critical. Although an established technique, manual microinjection is tedious, 
error-prone, low-throughput, and requires an expert researcher. From start to 
finish, the process takes about four hours and can result in many failed injections 
even with an experienced researcher. As a result, microinjection has a bottleneck 
effect on genetics research in C. elegans, greatly restricting the field. 
2.  Primary Ethical Considerations of Project 
Our project has three primary ethical concerns all related to accessibility: whether our 
solution is indeed more accessible than traditional microinjections, how we might be 
negatively impacting the researchers that can already perform microinjections, how 
increased accessibility may result in abuse of our product and the science around it, and 







2.1 Accessibility of our solution 
If our final solution is more complicated than existing technologies, then it’s 
worth must be called into question. If our project replaces the need for someone 
with a doctorate in genetics with someone with a doctorate in microfluidics, then 
we have not made microinjections more accessible.  
 2.2 Consequences of making research more accessible 
If our product is accessible to a researcher, they will find that C. elegans genetics 
research is also more accessible. Our project may deprive some C. elegans 
researchers that are capable of microinjection from future papers. In academia, 
success is frequently measured by an author’s publications. Current researchers 
may find that papers they planned on researching will now be addressed sooner 
by other labs. 
 2.3  Potential abuse of our product as a result of accessibility 
Along with increased accessibility will come increased use. As with any product, 
it is essential to consider how this product could be misused, particularly in the 
laboratory setting.  
 2.5 Safety 
It is important to consider all safety concerns that our product contains. Our 
product uses a variety of facilities and chemicals that are hazardous to one’s 
health. Some portions of the project also contain physical hazards.  
 2.4 The ethics of genetic engineering 
The field of genetic engineering is full of ethical questions that merit entire 
essays, these questions are not the focus of our ethical discussion. While genetic 
engineering is surely a consideration of our project, we intend to focus on the 
accessibility of a technology primarily and acknowledge that many discussions 







to consider the long-term consequences of our technology is of course 
problematic, but for brevity and to avoid the sometimes-infinite consequences of 
our decisions, this discussion must be omitted from this paper. 
3.  Is our product more accessible? 
Currently, based on the resources that Santa Clara University can provide, our product 
does make microinjection more accessible. However, increased accessibility and usage 
allows for potential misuse. Similarly, our product comes with multiple tradeoffs, 
revealing that a researcher’s location impacts accessibility more than anything else. 
 3.1  Required facilities and equipment  
Our product requires multiple facilities and a variety of equipment: research 
location determines feasibility of use. If one already can conduct C. elegans 
microinjections, the individual would still require a significant amount of 
resources to be capable of using our product.  
The microfluidics side of our product requires a cleanroom, and lots of equipment 
to accompany it (spin coaters, a mask aligner, volatile chemicals, etc.). The 
product also requires a microfluidic multiplexer, multiple air and vacuum sources, 
and the accompanying software to make the multiplexer work.  
Santa Clara University is fortunate to already have all of these facilities and 
materials, no new equipment has needed to be purchased to make our device 
work. If a C. elegans researcher find themselves in a similar position, then this 
product will work for them. Current prototypes are capable of injecting over 
twelve worms per use, compared to three for traditional methods. Our chip also 
has the unique ability to unclog its needles, saving more genetic reagent in 
comparison to traditional methods. Finally, our product can be used under any 
microscope, freeing microinjection from the inverted microscope. Our product 







However, while other facilities and universities have access to the required 
spaces, many C. elegans researchers do not. This is a violation of fairness; our 
product can only be used in higher-end research settings. Deciding reparations for 
this violation is difficult, the common-good approach would imply that those with 
access to our product have a duty to share their findings to those without access. 
In the C. elegans research community, people are much more forthcoming with 
their findings, but our product does not diminish the barrier between C. elegans 
researchers with access to higher end facilities versus those with access to lower 
end facilities.    
3.2 Required personnel 
Our product requires one person for complete fabrication. It does not require 
someone with a doctorate, but fabrication of the product relies on someone having 
basic knowledge of microfluidics. Hence, the knowledge required to complete 
microinjection is less severe.  
Our product requires two people to operate. Operation of this device is very 
difficult without two people, primarily due to the software that interacts with this 
chip. On a per capita basis, our product requires more than traditional methods; 
however, it also increases opportunities for a workforce of undergraduate research 
students looking for work in labs. Allowing undergraduates to participate in the 
research and assist in operations would also afford the PI more time to examine 
topics that are less familiar to other students. In general, despite the increase in 
personnel, the project as a whole is more accessible to everyone; allowing for 
better division of labor and more rapid progress.  
 3.3 People with unsteady hands 
Compared to traditional methods, our product is easier to use for people with 
unsteady hands. Operation of the chip requires basic microscopy skills and the 
ability to use a computer mouse to interact with the microfluidic software. 







lightly tapping on the back of a needle to perform microinjection. Twitchy 
motions on the micromanipulator will prevent alignment of the needle with the 
worm’s body, too hard of a tap may result in the development of sepsis in a worm.  
4. Impact of more accessible research 
As mentioned in Section 1.2, microinjection is a major rate limiting step for C. elegans 
genetics research. Assuming a researcher can access and use our product, they will find 
this is no longer then case: microinjections can be performed by anyone, and they can be 
performed quickly. Hence pros and cons must be weighed, particularly as it pertains to 
the ensuing publications. Overall, our product long term benefits outweigh its immediate 
consequences.  
4.1 Increased competition 
A person capable of performing microinjection already will find more 
competition in a field she was previously isolated in. Immediately, this will have a 
negative impact to said researcher. Papers and topics that the researcher had 
“stored,” awaiting until the researcher had time to address them, may sooner be 
addressed by other researchers. This will result in the researcher capable of 
microinjection losing a potential paper, while the researchers with new access to 
microinjection will gain a paper.  
However, this paper would be going from someone with a PhD’s worth of 
experience to someone with potentially much less experience. Initial publications 
are crucial to an early researcher’s career, but publishable topics are hard to come 
by. Thus, a publication from our product could help someone with a master’s or 
bachelor’s degree more than someone with a doctorate. While the person with the 
doctorate would surely benefit from a publication, she would only be adding to a 
presumably impressive resume. Therefore, increased competition as a result of 
our product may help lower tiers of researchers and allow papers to have more 
impact on a person’s career.  







The doctor that lost a paper to competition can still benefit from our product: 
more genetics research in C. elegans will be conducted. The fields of biology and 
bioengineering benefit from the idea that research ultimately asks more questions 
than it answers. For every newfound understanding of C. elegans genetics as a 
result of our product, more questions can be asked, and the understanding of the 
model organism increases. Hence, one initial paper lost might be multiple papers 
gained. In general, as our understanding of C. elegans genetics increases, so too 
will the public’s ability to use this knowledge.  
5. Acceptable Use of our Product 
As with all products, the usage of our product in a lab requires ethical considerations. The 
usage of the product will vary by experience level, and it is essential to recall that all use 
impacts the health of living animals. The user is strongly encouraged to consult the 
Biomedical Engineering Society’s (BMES) Code of Ethics prior to using our product.  
5.1  Use by an experienced doctor  
A primary investigator with experience in microinjection that chooses to use our 
product may find the product is more time consuming to use initially. Both the PI 
and any students involved will need some familiarity with microfluidics. 
However, such education would serve to further the education of everyone. 
Education would also prevent any research assistants from being used as mere 
operators of a product they do not understand. Usage without teaching stands in 
direct conflict with a biomedical engineer’s obligation “to train biomedical 
engineering students in proper professional conduct” according to the BMES 
Code of Ethics.   
 
 5.2 Use by a graduate or undergraduate 
Our product increases the genetic engineering accessibility to graduates and 







are consequences to this reduced knowledge, though, such as sympathy for any C. 
elegans animals used in this product may be less for a graduate or undergraduate 
in comparison to someone with a doctorate. This lack of sympathy is the result of 
presumably less interaction with the animals and may result in mistreatment of the 
animals (See Section 5.3).  
 5.3 Animal rights 
Our chip can inject more worms per unit of time, and thus it is also capable of 
hurting more worms per unit of time. Though C. elegans populations are easy to 
maintain, biomedical engineers “[respect] the rights of […] animal subjects” per 
the BMES Code of Ethics. Although the animals are easy to raise, they have a 
universal right to not be recklessly hurt and killed. Users of our product have a 
duty to uphold this right in the course of their research.  
Our product does kill more animals per unit of time, but the procedure that it 
conducts kills a smaller proportion of animals in comparison to traditional 
methods. The success rate of microinjections is higher, but the user may decide 
that the overall losses the product causes are unacceptable.  
6.  Product Safety  
All users have a right to their own safety and a similar duty to maintain their own and the 
safety of others. Our product both introduces and mitigates risks in comparison to 
traditional microinjection. While mitigation of existing risks is beneficial to all, the 
introduction of some new risks may outweigh whatever mitigation is introduced. The 
danger that any of these risks pose is entirely based on user expertise and experience.  
6.1  Risks introduced 
The majority of the new risks that we introduce are the result of the additional 
facilities and equipment that our project requires for fabrication (See Section 3.1). 
Our project calls for the use of chemicals that are known to be hazardous (toxic, 







can be mitigated by wearing proper protective equipment (PPE) and following lab 
safety protocols, and eyes can be protected from UV exposure. However, other 
exposed areas of the skin (mouth, neck, etc.), cannot be protected from the UV 
light, and it is recommended that the user face away from the machine during 
exposure times.  
Our product fabrication also requires that some microinjection equipment be used 
in untraditional ways. The micromanipulator and inverted microscope are used to 
break micron scale needle tips from traditional microinjection needles. While 
protocols have been created to mitigate the risks and handling of these micron 
size needle fragments, always consult with the owner of the equipment before 
using it as our product directs. PPE should always be worn to avoid fragment 
contact with the skin, and eyewear is essential to avoid getting fragments in the 
user’s eyes.  
No injuries have occurred over the course of this project while completing any 
procedures. Despite the risks introduced, current safety protocols in most lab 
spaces should be enough to mitigate risks and potential harm.  
 6.2 Risks mitigated 
Our product eliminates multiple dangerous elements required by traditional 
microinjection. It no longer requires the user to directly glass with molten sections 
and decreases the need for exposed flames in lab. Our product eliminates the 
requirement of mouth-pipetting to load genetic material into microinjection 
needles. While most of these genetic materials have little immediate risk to a 
user’s health, mouth pipetting should always be avoided. Our product also 
diminishes the probability that a user impales their hand on a needle when loading 
genetic material into a microinjection needle. 
 6.3 Overall 
Traditional methods have higher hazard risk than our final solution. Our solution 







require that any used chemicals come into even remote contact with the mouth. 
Traditional microinjection also has a high probability of physical injury, via either 
puncture wounds or burns. It is hard to mitigate the probability of these risks, as 
they are necessarily introduced for the sake of traditional microinjection.  
 
 
 
 
 
